A February 2026 recall covering hundreds of thousands of newer pumps. California bellwether cases that have survived both summary judgment and appellate challenge. And as of mid-2026, no global settlement in sight. The Medtronic MiniMed insulin pump lawsuit landscape has never been more active, or more consequential, for the roughly 800,000 diabetic patients across the country who have used one of these devices. This breaking-news recap covers every layer of the litigation, why no federal MDL has formed yet, and what injured patients must do before their legal clock runs out.
Two Major Recalls, One Dangerous Pattern
The Medtronic MiniMed insulin pump lawsuit story begins with a structural defect that the FDA ultimately classified as its most serious category of risk. In November 2019, Medtronic initiated a voluntary recall of its MiniMed 630G and 670G pumps after a retainer ring inside the device was found to crack or break under normal use. When the ring fails, the insulin cartridge can misalign — causing the pump to over-deliver or under-deliver insulin. Over-delivery triggers hypoglycemia, which can escalate to seizures, coma, or death. Under-delivery causes hyperglycemia and potentially fatal diabetic ketoacidosis (DKA). According to FDA medical device recall records, Medtronic had already received 26,421 complaints — including 2,175 injury reports and one confirmed death — before pulling the devices from use.
The FDA formally classified the retainer-ring recall as Class I in February 2020, meaning the agency determined there was a reasonable probability that use of the product would cause serious adverse health consequences or death. The original recall covered 322,005 pumps manufactured before October 2019 (630G) and August 2019 (670G). In October 2021, Medtronic expanded the recall proactively, replacing all 600-series pumps equipped with clear retainer rings with black-ring models — bringing the total number of affected devices to approximately 500,000 units.
Plaintiffs’ attorneys in the ongoing Medtronic MiniMed insulin pump lawsuit filings frequently cite Medtronic’s prior history with its older Paradigm pump line, which was the subject of multiple FDA recalls between 2009 and 2017 for blocked membranes, infusion set defects, and motor malfunctions. That pattern, they argue, is evidence of a systemic and long-standing quality-control failure — not an isolated engineering mistake. The February 2026 recall of newer 700-series pumps for a separate but equally serious delivery defect has only strengthened that argument.
The February 2026 Class II Recall: 562,659 More Pumps
Just as the original retainer-ring litigation was gaining momentum in state courts, Medtronic began communicating a second significant recall to customers starting February 13, 2026 — this time targeting its newer 700-series pumps. The recall covers 562,659 devices across three models: 13,811 MiniMed 700G pumps, 95,704 MiniMed 770G pumps, and 453,144 MiniMed 780G pumps. The defect involves potential insulin over-delivery or under-delivery issues that the FDA classified as a Class II recall, indicating a risk of temporary or medically reversible adverse health consequences — though plaintiffs’ attorneys note that insulin dosing errors can, and do, turn fatal.
According to FDA safety recall announcements, Medtronic used a multi-channel outreach approach that included email, SMS, certified mail, and in-app notifications to reach affected customers. For patients already navigating the original Class I litigation, the February 2026 recall raised an immediate question: does injury from a 700-series pump give rise to a separate claim? The short answer, according to attorneys actively filing in this space, is yes — provided the patient suffered a documented adverse event and can establish a causal link to the device malfunction. The Class II classification does not limit a plaintiff’s ability to pursue damages; it is an FDA administrative designation, not a legal ceiling on liability.
The timing of the February 2026 recall is legally significant in another respect. It resets the discovery clock for many patients who may not have known their device was defective, and it creates fresh evidence that Medtronic was aware of delivery-related risks across multiple pump generations. Plaintiffs’ lawyers are already citing the 780G recall in newly filed complaints as corroborating evidence of a broader pattern of inadequate design and post-market surveillance.
Where the Litigation Stands in Mid-2026
As of mid-2026, the Medtronic MiniMed insulin pump lawsuit docket remains relatively concentrated but is showing signs of growth. According to a January 23, 2026 SEC filing by MiniMed Group Inc., there are four active lawsuits filed on behalf of 12 individuals in the United States: three cases coordinated in California State Court and one case pending in the U.S. District Court for the Western District of New York. That figure reflects only cases formally on the docket at the time of the filing and does not capture claims in pre-litigation demand or investigation stages, which attorneys in this space describe as a growing pipeline.
The most recent confirmed resolution in the litigation is an October 2024 wrongful death settlement in Kentucky, which was resolved for an undisclosed amount. While the confidential terms limit what can be said publicly, the fact that Medtronic agreed to settle a wrongful death claim signals that the company recognizes meaningful exposure in cases with the most serious outcomes. As of mid-2026, no global settlement framework has been announced, and Medtronic has not indicated it is pursuing a consolidated resolution of the pending state court claims.
For patients injured by either the 600-series or 700-series pumps, the practical takeaway is straightforward: the litigation is active, settlements are occurring, and the window to file is closing. Waiting for a headline-grabbing global settlement before consulting an attorney is a strategy that carries serious risk of missing applicable deadlines.
California Bellwether Cases Survive Medtronic’s Preemption Defense
The most consequential legal development of 2026 — and arguably of the entire MiniMed litigation to date — is the survival of the California bellwether cases through both summary judgment and appellate challenge. As of mid-2026, those cases are moving toward trial, a milestone that shifts the dynamics of every other pending and prospective claim in the country.
To understand why this matters, it helps to understand the defense Medtronic has used most aggressively: federal preemption. Under the Medical Device Amendments of 1976 to the Federal Food, Drug, and Cosmetic Act, Class III medical devices that receive FDA premarket approval (PMA) are subject to an express preemption clause. Medtronic has argued in multiple jurisdictions that because the MiniMed pumps received PMA clearance, state-law product liability claims are preempted — effectively wiping out plaintiffs’ ability to sue in federal court.
That argument has succeeded in some federal venues, which is one reason the California state court docket has become the center of gravity for this litigation. California courts have consistently held that plaintiffs asserting parallel claims — claims alleging that the manufacturer violated both federal device regulations and state-law duties simultaneously — are not preempted. The appellate courts in California have now affirmed that reasoning in the context of the MiniMed cases specifically, rejecting Medtronic’s attempt to extinguish the claims before trial.
With three coordinated California cases surviving every pretrial challenge Medtronic has mounted, those cases now function as de facto bellwethers for the broader litigation. How a California jury evaluates Medtronic’s conduct, and what damages it awards, will heavily influence settlement negotiations for every other claimant in the pipeline.
Why There Is No Federal MDL — And What That Means for You
One of the most common questions prospective plaintiffs ask is why there is no federal multidistrict litigation (MDL) consolidating all MiniMed claims the way other major device litigations — hip implants, hernia mesh, surgical staplers — have been consolidated before a single federal judge. As of August 2026, the answer is straightforward: no class action or federal MDL exists consolidating personal injury or wrongful death claims against Medtronic related to insulin pump malfunctions.
The primary reason is the preemption landscape described above. Because federal courts in many circuits have dismissed MiniMed claims on preemption grounds, the plaintiff pool eligible to litigate in federal court is thin. Without a sufficient concentration of federal claims, the Judicial Panel on Multidistrict Litigation has no basis to consolidate them. The action is in state court — principally California — and that is where plaintiffs with viable claims are filing.
For injured patients, the absence of an MDL has practical consequences. There is no centralized docket to monitor, no lead plaintiff’s counsel appointed by a federal judge, and no court-supervised discovery process that would automatically benefit every claimant. Each case must be evaluated, filed, and litigated individually or through state-level coordination. That makes the choice of attorney more consequential, not less — because there is no safety net of MDL infrastructure to fall back on.
It also means that the statute of limitations is not tolled by MDL membership. Every potential plaintiff is running on their own individual clock, and that clock does not pause because litigation is ongoing elsewhere.
What Injured Patients Must Do Right Now
If you or a family member suffered a serious injury — hypoglycemia, seizure, coma, DKA, or death — while using a Medtronic MiniMed insulin pump from any series, including the 630G, 670G, 700G, 770G, or 780G, there are several steps you should take immediately.
Preserve the device. Do not return the pump to Medtronic, even if the company has issued a recall and is offering a replacement. The physical device is potentially critical evidence. Photograph it, document the model and serial number, and store it in a safe location. Instruct anyone in your household not to discard it.
Gather your medical records. Request complete records from every provider who treated you for the adverse event — emergency room, hospital, endocrinologist, and primary care. These records establish the injury, its severity, and its timing relative to pump use.
Document the malfunction. If you received any communication from Medtronic about the recall — email, letter, in-app notification, or phone call — preserve it. If you reported the malfunction to Medtronic’s customer service line, note the date, time, and content of that conversation.
Consult an attorney before the deadline. Product liability statutes of limitations vary by state, but most range from two to four years from the date of injury or the date the injury was discovered. In some states, wrongful death claims have shorter windows. With the California cases now heading toward trial and the February 2026 recall putting new pump generations in play, 2026 is a critical year for potential claimants to act. An attorney experienced in medical device litigation can evaluate whether your claim is viable, which jurisdiction offers the best strategic posture, and whether the parallel-claim framework that has succeeded in California applies to your facts.
The MiniMed litigation is no longer in its early stages. Bellwether trials are approaching. Settlements are occurring. And the companies involved are well-represented by sophisticated defense teams. Patients who wait — hoping for more news, a larger docket, or a cleaner resolution — risk losing their right to participate entirely.
Frequently Asked Questions
Who is eligible to file a Medtronic MiniMed insulin pump lawsuit?
Any patient who used a recalled Medtronic MiniMed insulin pump — including the 630G, 670G, 700G, 770G, or 780G — and suffered a serious adverse event such as hypoglycemia, seizure, coma, diabetic ketoacidosis, or death may have a viable claim. Eligibility depends on whether a causal link can be established between the device malfunction and the injury, whether the applicable statute of limitations has run, and whether the claim can be structured as a parallel claim that survives federal preemption analysis. Family members of patients who died from pump-related complications may be eligible to bring wrongful death claims, subject to state-specific rules. The best way to assess eligibility is through a confidential consultation with a medical device attorney.
What is the difference between the Class I and Class II MiniMed recalls?
The FDA uses recall classifications to communicate the level of health risk associated with a defective product. A Class I recall — like the 2020 recall of the 630G and 670G pumps for retainer ring failures — indicates that the FDA has determined there is a reasonable probability that use of the product will cause serious adverse health consequences or death. It is the most serious classification. A Class II recall — like the February 2026 recall of the 700G, 770G, and 780G pumps — indicates a risk of temporary or medically reversible adverse health consequences, or a remote probability of serious harm. In legal terms, however, the classification does not determine the value or viability of a personal injury claim. A patient who suffered a severe hypoglycemic episode from a Class II-recalled device may have an equally compelling claim as a patient harmed by a Class I-recalled device, depending on the facts and circumstances.
Why did some federal courts dismiss MiniMed lawsuits while California courts allowed them to proceed?
The divergence comes down to how different courts have interpreted the federal preemption doctrine as applied to PMA-cleared medical devices. Under the Medical Device Amendments of 1976, state-law claims that impose requirements different from or in addition to federal device regulations are expressly preempted. Many federal courts have read this broadly and dismissed MiniMed claims on those grounds. California state courts, however, have recognized an important exception: claims that run parallel to federal requirements — alleging that the manufacturer violated its own FDA-approved specifications and that this violation also breached state-law duties — are not preempted. The California appellate courts affirmed this reasoning in the context of the MiniMed cases in 2026, which is why the three coordinated California cases are now the leading edge of the litigation and are advancing toward trial.
Has Medtronic settled any MiniMed insulin pump lawsuits?
Yes. The most recent publicly confirmed resolution is an October 2024 wrongful death settlement in Kentucky, which was resolved for an undisclosed amount. Prior settlements have also occurred, though terms are typically kept confidential. As of mid-2026, no global settlement framework has been reached, and the California bellwether cases — which have survived every pretrial challenge — are advancing toward trial. The progression of those cases toward a jury verdict is expected to exert significant pressure on settlement negotiations for all remaining claimants. Patients should not interpret the absence of a headline settlement as evidence that claims lack value; confidential individual settlements are a routine feature of medical device litigation.
What is the statute of limitations for filing a MiniMed insulin pump lawsuit?
Statutes of limitations for product liability and wrongful death claims vary significantly by state, typically ranging from one to four years from the date of injury or the date the plaintiff discovered — or reasonably should have discovered — that the injury was caused by the device. Some states apply a discovery rule that can extend the filing window for patients who were not immediately aware of the connection between their adverse event and a pump malfunction. The February 2026 recall notification may reset or extend the limitations period for some 700-series pump patients, depending on applicable state law. Because these deadlines are strictly enforced and vary by jurisdiction, consulting a medical device attorney as soon as possible is essential. Missing the statute of limitations extinguishes the right to file entirely, regardless of how strong the underlying claim may be.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.